Skip to main content

Table 1 EU-COVAT-1-AGED intervention in Part B – 4th vaccination doseb

From: A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Cohort

Vaccination prior to study entry

Arm

Study intervention: 4th vaccination dosea

Cohort 4

BNT162b2 + BNT162b2 + BNT162b2

7

BNT162b2

8

mRNA-1273

Cohort 5

BNT162b2 + BNT162b2 + mRNA-1273

9

BNT162b2

10

mRNA-1273

Cohort 6

mRNA-1273 + mRNA-1273 + mRNA-1273

11

BNT162b2

12

mRNA-1273

Cohort 7

mRNA-1273 + mRNA-1273 + BNT162b2

13

BNT162b2

14

mRNA-1273

Cohort 8

ChAdOx-1-S + ChAdOx-1-S + BNT162b2

15

BNT162b2

16

mRNA-1273

Cohort 9

ChAdOx-1-S + ChAdOx-1-S + mRNA-1273

17

BNT162b2

18

mRNA-1273

  1. aAdministered at least 1 month after the 3rd pre-study vaccination
  2. bFor intervention in Part A (3rd vaccination dose) see Additional file 1
Back to article page

Trials

ISSN: 1745-6215